Core Insights - Castle Biosciences, Inc. will present data on the DecisionDx-Melanoma test at the 11th World Congress of Melanoma and the 21st European Association of Dermato-Oncology Congress, highlighting its role in risk stratification for patients with stage IIB-IIC cutaneous melanoma [1][2] Group 1: DecisionDx-Melanoma Test - The DecisionDx-Melanoma test provides significant biological insights that enhance traditional staging, allowing clinicians to tailor surveillance and treatment plans based on individual risk of metastasis [2] - The test has been shown to improve melanoma outcomes by identifying patients who may benefit from intensified monitoring and adjuvant therapy [2][6] - DecisionDx-Melanoma has been ordered over 191,000 times for patients diagnosed with cutaneous melanoma, demonstrating its clinical value supported by more than 50 peer-reviewed studies [6][7] Group 2: Research Findings - A study presented at EADO indicates that DecisionDx-Melanoma effectively stratifies melanoma-specific survival and overall survival in patients with stage IIB-IIC cutaneous melanoma, with a p-value of less than 0.001 [5] - Another study shows that the test can identify patients with localized cutaneous melanoma at high risk of CNS metastasis within the first three years post-diagnosis, with a hazard ratio of 9.21 [5] - The DecisionDx-Melanoma Class 2B result is a significant predictor of CNS metastasis, emphasizing the need for more frequent imaging surveillance for high-risk patients [5]
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma